849773-56-4

Upstream product

• 704888-95-9 N-isopropoxy-1,1'-biphenyl-4-sulfonamide 
• 849773-54-2 tert-butyl (2S)-4-{[(benzyloxy)carbonyl]amino}-2-hydroxybutanoate 
• 40371-50-4 S-4-benzyloxycarbonylamino-2-hydroxybutyric acid 

Downstream Products

• 849773-58-6 (R)-4-Benzyloxycarbonylamino-2-[(biphenyl-4-sulfonyl)-isopropoxy-amino]-butyric acid 
• 853755-40-5 (R)-2-[(Biphenyl-4-sulfonyl)-isopropoxy-amino]-4-{4-[3-(3-{(R)-3-[(biphenyl-4-sulfonyl)-isopropoxy-amino]-3-carboxy-propylcarbamoyl}-propylcarbamoyl)-benzoylamino]-butyrylamino}-butyric acid 
• 849773-61-1 {(R)-3-Benzyloxycarbamoyl-3-[(biphenyl-4-sulfonyl)-isopropoxy-amino]-propyl}-carbamic acid benzyl ester 
• 849773-60-0 C₃₃H₄₅N₃O₇SSi 
• 1061742-79-7 (R)-tert-butyl 4-benzamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)butanoate 
• 1061742-95-7 (R)-tert-butyl 2-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoate 
• 1061742-81-1 (R)-4-benzamido-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-butanoic acid 
• 1061742-97-9 (R)-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanoic acid 
• 1061742-44-6 (R)-N-(4-(hydroxyamino)-3-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-oxobutyl)benzamide 
• 1061742-49-1 (R)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-4-(2-phenylacetamido)butanamide 
• 1061742-83-3 C₃₂H₄₃N₃O₆SSi 
• 1061742-99-1 C₃₃H₄₅N₃O₆SSi 

Relevant academic research and scientific papers

Diagnostic agents selective against metalloproteases

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly la

N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity

Matrix metalloproteinases (MMPs) have been shown to be involved in tumor-induced angiogenesis. In particular, MMP-2, MMP-9, and MMP-14 have been reported to be crucial for tumor angiogenesis and the formation of metastasis, thus becoming attractive targets in cancer therapy. Here, we report our optimization effort to identify novel N-isopropoxy-arylsulfonamide hydroxamates with improved inhibitory activity toward MMP-2, MMP-9, and MMP-14 with respect to the previously discovered compound 1. A new series of hydroxamates was designed, synthesized, and tested for their antiangiogenic activity using in vitro assays with human umbilical vein endothelial cells (HUVECs). A nanomolar MMP-2, MMP-9, and MMP-14 inhibitor was identified, compound 3, able to potently inhibit angiogenesis in vitro and also in vivo in the matrigel sponge assay in mice. Finally, X-ray crystallographic and docking studies were conducted for compound 3 in order to investigate its binding mode to MMP-9 and MMP-14.

ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS

The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below ???????? (M)-L-(M')?????(I) wherein M and M', the same or different from each other, represent the residues of the mctalloprotcascs inhibitors of formula (II) wherein R, R1, R2, R3, G and n have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.

Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors

The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, R4, R5, n and m have the meanings r

N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP

Structural manipulation of the pharmacophoric model of type A selective MMP inhibitors (MMPi), obtained by the insertion of some alkyl substituents R 2 possessing an appropriate geometry, steric bulkiness and lipophilicity, is able to improve p